Spanish pharmaceutical company Almirall has picked Karin Louise Dorrepaal to sit on its board of directors as an independent board member.
She is the first woman to join the Barcelona-based company’s ten member board and has gained extensive international experience in the pharmaceutical sector during her 25 year career.
This includes six years serving as director of global business unit diagnostic imaging and supply chain and procurement at Bayer Pharma and sitting on the board of Schering for two years.
Dorrepaal currently holds non-executive positions in healthcare sector and consultancy companies.
Earlier this month, she was appointed to the supervisory board of German specialty pharma company Paion, where she replaced Grünenthal chief executive Harald Stock.
Dorrepaal’s appointment to the Almirall board will take effect from January 1, 2013, and will be ratified at the company’s next annual general meeting.